A Study of LY3522348 in Healthy Participants

Phase 1 Completed 65 enrolled Eli Lilly and Company

RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3522348 gets into the bloodstream and how long it takes the body to eliminate it. This study has two parts: Part A will last up to about six weeks and Part B will last up to about eight weeks for each participant.

Timeline

Start: 2020-10-15
Primary completion: 2021-08-17
Completion: 2021-08-17

Publications

Fukuda T, Thompson BR, Brouwers B, Qian HR, Wang W, Morse BL, LaBell ES, Durham TB, Konig M, Haupt A, Benson CT, MacKrell J. LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults. Diabetes Ther. 2025 Jul;16(7):1399-1415. doi: 10.1007/s13300-025-01752-5. Epub 2025 May 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3522348	Small molecule	5 mg	Oral
Subject	LY3522348	Small molecule	15 mg	Oral
Subject	LY3522348	Small molecule	50 mg	Oral
Subject	LY3522348	Small molecule	120 mg	Oral
Subject	LY3522348	Small molecule	150 mg	Oral
Subject	LY3522348	Small molecule	290 mg	Oral
Subject	LY3522348	Small molecule	380 mg	Oral
Subject	Midazolam	Small molecule	200 ug	Oral

Indications

No indication recorded.